Description
Background:
Complement Hemolysis 50 (CH50) assay serves as a cornerstone in the assessment of complement system function, providing valuable insights into immune response efficiency and susceptibility to infectious diseases. By measuring the serum’s ability to lyse erythrocytes, the CH50 assay evaluates the overall activity of the classical pathway of complement activation. The Human CH50 ELISA Kit offers a reliable method for quantifying CH50 levels in human serum samples, facilitating studies aimed at understanding immune system function, autoimmune disorders, and infectious diseases.
Pathways and Relevance:
The Human CH50 ELISA Kit is instrumental in elucidating pathways associated with complement activation, immune complex-mediated diseases, and host defense mechanisms. By quantifying CH50 levels, researchers can assess complement system activity, monitor disease progression, and evaluate therapeutic responses in conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and sepsis. Furthermore, CH50 serves as a prognostic marker for disease severity and treatment outcomes, highlighting its relevance in patient management and personalized medicine approaches.
Current Research and Ongoing Discoveries:
Researchers worldwide are leveraging the Human CH50 ELISA Kit to advance our understanding of immune regulation and complement-mediated diseases. Ongoing research endeavors include investigating the mechanisms underlying complement activation, identifying novel biomarkers for disease diagnosis and prognosis, and developing targeted therapies for complement-related disorders. Additionally, researchers are exploring the potential of CH50 as a therapeutic target in autoimmune diseases, inflammatory conditions, and infectious diseases, driving innovation and shaping the future of immunology and clinical medicine.
Validated against seven points for a “GOLD RING” Standard Quality ELISA – the benchmark sign for Krishgen Quality. The The GENLISA ELISA kits are used for assessing the specific biomarker in samples analytes which may be human serum, plasma, biological fluids and cell culture supernatant. The kit uses indirect sandwich assay with double antibodies – capture and detection to ensure a high degree of sensitivity and specificity in the estimation of Chemokine C-X-C-Motif Receptor 3 (CXCR3);
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: kbiinfo@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!